Active Ingredient: Adalimumab
Adalimumab is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
20 - 40 mg
From 20 To 40 mg once every 14 day(s)
40 mg
The recommended dose of adalimumab for paediatric patients with uveitis from 2 years of age is based on body weight (Table). adalimumab is administered via subcutaneous injection. In paediatric uveitis, there is no experience in the treatment with adalimumab without concomitant treatment with methotrexate.
Adalimumab Dose for Paediatric Patients with Uveitis:
| Patient Weight | Dosing Regimen |
|---|---|
| <30 kg | 20 mg every other week in combination with methotrexate |
| ≥30 kg | 40 mg every other week in combination with methotrexate |
When adalimumab therapy is initiated, a loading dose of 40 mg for patients <30 kg or 80 mg for patients ≥30 kg may be administered one week prior to the start of maintenance therapy. No clinical data are available on the use of a adalimumab loading dose in children <6 years of age.
There is no relevant use of adalimumab in children aged less than 2 years in this indication.
It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a yearly basis.
Adalimumab may be available in other strengths and/or presentations depending on the individual treatment needs.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
